Skip to main content
Entheon Biomedical Corp. logo

Entheon Biomedical Corp. — Investor Relations & Filings

Ticker · ENBI ISIN · CA29383X2023 LEI · 894500N2J7IXCCDRWU50 CSE Professional, scientific and technical activities
Open in API
Filings indexed 369 across all filing types
Latest filing 2022-12-06 Regulatory Filings
Country CA Canada
Listing CSE ENBI

About Entheon Biomedical Corp.

https://www.entheonbiomedical.com/

Entheon Biomedical Corp. is a biotechnology research and development company focused on creating therapeutic solutions for addiction and substance use disorders. The company specializes in the development and commercialization of psychedelic medicines, particularly dimethyltryptamine (DMT). Entheon aims to progress psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, and novel compounds tailored for treating these complex conditions.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings
2022-12-06 English
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a corporate update announcement from Entheon Biomedical Corp. regarding its subsidiaries HaluGen Life Sciences and Lobo Genetics. It provides information about ceasing sales of certain products and contact details, but does not contain financial statements, detailed financial performance, or regulatory filings. There is no indication of an annual report, earnings release, management discussion, or other detailed financial or governance report. The document is a general corporate update and does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification either, but rather a general corporate news update. Given the absence of a more specific category, the best fit is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories. The document length (5555 characters) and content confirm it is not a brief report publication announcement or a short notice but a standard corporate update.
2022-12-01 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS' and covers financial data for the three and nine months ended August 31, 2022 and 2021. It includes detailed unaudited financial statements such as statements of financial position, comprehensive loss, changes in equity, and cash flows. The presence of actual financial data and analysis for a period shorter than a full fiscal year (interim period) confirms this is an interim financial report. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2022
2022-10-31 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification form (Form 52-109FV2) signed by the CFO certifying the accuracy and fair presentation of the interim financial report and interim MD&A for the period ended August 31, 2022. It explicitly states it is a certification of interim filings for a venture issuer and does not contain the actual financial data or analysis itself, but rather attests to the filings. The document length is short (3042 characters) and it is primarily an officer certification. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than the interim report itself (IR).
2022-10-31 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CEO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended August 31, 2022. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. It references an interim report but does not include the report itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is short (3030 characters), consistent with a certification letter rather than a full report.
2022-10-31 English
Interim MD&A - English.pdf
Regulatory Filings
2022-10-31 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.